Trial Profile
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tazarotene/ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- 24 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Aug 2012 New trial record